Loss of heterozygosity at the mannose 6-phosphate insulin-like growth factor 2 receptor (M6P/IGF2R) locus predisposes patients to radiation-induced lung injury

Feng Ming Kong, Mitchell S. Anscher, Thomas A. Sporn, Mary K. Washington, Robert Clough, Mary H. Barcellos-Hoff, Randy L. Jirtle

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Purpose: To investigate the relationship between loss of heterozygosity (LOH) at the mannose 6-phosphate/insulin-like growth factor 2 receptor (M6P/IGF2R) gene locus and the development of radiation-induced lung injury. Material and Methods: Thirty-five lung cancer patients with both stored plasma for Transforming Growth Factor β1 (TGFβ1) analysis and sufficient quantities of archival pathology tissue to screen for LOH were studied. All patients had been treated with thoracic radiotherapy for their malignancy and had radiographically detectable tumor present before beginning radiotherapy. Tumor and normal cells were microdissected from archival lung cancer pathology specimens. Two polymorphisms in the 3′ untranslated region of the M6P/IGF2R were used to screen for LOH. Plasma TGFβ1 levels were measured using acid-ethanol extraction and an ELISA. TGFβ1 and M6P/IGF2R protein expression was estimated by immunofluorescence and immunohistochemical staining. Symptomatic radiation pneumonitis was scored according to National Cancer Institute Common Toxicity Criteria without knowledge of the results of TGFβ or LOH analyses. Results: Of the 35 patients, 10 were homozygous for this polymorphism (noninformative) and were excluded. Of the 25 informative patients, 13 had LOH. Twelve of 13 patients with LOH had increased pretreatment plasma TGFβ1 levels, vs. 3/12 patients without LOH (p < 0.01). A decrease or loss of M6P/IGF2R protein in the malignant cell accompanied by increased latent TGFβ1 protein in extracellular matrix and tumor stroma was found in tumors with LOH, suggesting that this mutation resulted in loss of function of the receptor. Seven of 13 (54%) LOH patients developed symptomatic radiation-induced lung injury vs. 1/12 (8%) of patients without LOH (p = 0.05). Conclusions: Loss of the M6P/IGF2R gene strongly correlates with the development of radiation pneumonitis after thoracic radiotherapy (RT). Furthermore, patients with LOH (in the setting of measurable tumor) are much more likely to have elevated plasma TGFβ, suggesting an inability to normally process this cytokine. Thus, loss of the M6P/IGF2R gene may predispose patients to the development of radiation-induced lung injury.

Original languageEnglish (US)
Pages (from-to)35-41
Number of pages7
JournalInternational Journal of Radiation Oncology Biology Physics
Volume49
Issue number1
DOIs
StatePublished - Jan 1 2001

Fingerprint

Somatomedin Receptors
insulin
Loss of Heterozygosity
Lung Injury
loci
lungs
phosphates
Radiation
radiation
Transforming Growth Factors
tumors
Radiation Pneumonitis
Neoplasms
Radiotherapy
genes
radiation therapy
Lung Neoplasms
cancer
polymorphism
mannose-6-phosphate

Keywords

  • Complications
  • Mannose 6-phosphate/insulin-like growth factor type 2 receptor
  • Radiation pneumonitis

ASJC Scopus subject areas

  • Radiation
  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

Loss of heterozygosity at the mannose 6-phosphate insulin-like growth factor 2 receptor (M6P/IGF2R) locus predisposes patients to radiation-induced lung injury. / Kong, Feng Ming; Anscher, Mitchell S.; Sporn, Thomas A.; Washington, Mary K.; Clough, Robert; Barcellos-Hoff, Mary H.; Jirtle, Randy L.

In: International Journal of Radiation Oncology Biology Physics, Vol. 49, No. 1, 01.01.2001, p. 35-41.

Research output: Contribution to journalArticle

Kong, Feng Ming ; Anscher, Mitchell S. ; Sporn, Thomas A. ; Washington, Mary K. ; Clough, Robert ; Barcellos-Hoff, Mary H. ; Jirtle, Randy L. / Loss of heterozygosity at the mannose 6-phosphate insulin-like growth factor 2 receptor (M6P/IGF2R) locus predisposes patients to radiation-induced lung injury. In: International Journal of Radiation Oncology Biology Physics. 2001 ; Vol. 49, No. 1. pp. 35-41.
@article{25464d997feb4b26ba6f1bfb7217a9cd,
title = "Loss of heterozygosity at the mannose 6-phosphate insulin-like growth factor 2 receptor (M6P/IGF2R) locus predisposes patients to radiation-induced lung injury",
abstract = "Purpose: To investigate the relationship between loss of heterozygosity (LOH) at the mannose 6-phosphate/insulin-like growth factor 2 receptor (M6P/IGF2R) gene locus and the development of radiation-induced lung injury. Material and Methods: Thirty-five lung cancer patients with both stored plasma for Transforming Growth Factor β1 (TGFβ1) analysis and sufficient quantities of archival pathology tissue to screen for LOH were studied. All patients had been treated with thoracic radiotherapy for their malignancy and had radiographically detectable tumor present before beginning radiotherapy. Tumor and normal cells were microdissected from archival lung cancer pathology specimens. Two polymorphisms in the 3′ untranslated region of the M6P/IGF2R were used to screen for LOH. Plasma TGFβ1 levels were measured using acid-ethanol extraction and an ELISA. TGFβ1 and M6P/IGF2R protein expression was estimated by immunofluorescence and immunohistochemical staining. Symptomatic radiation pneumonitis was scored according to National Cancer Institute Common Toxicity Criteria without knowledge of the results of TGFβ or LOH analyses. Results: Of the 35 patients, 10 were homozygous for this polymorphism (noninformative) and were excluded. Of the 25 informative patients, 13 had LOH. Twelve of 13 patients with LOH had increased pretreatment plasma TGFβ1 levels, vs. 3/12 patients without LOH (p < 0.01). A decrease or loss of M6P/IGF2R protein in the malignant cell accompanied by increased latent TGFβ1 protein in extracellular matrix and tumor stroma was found in tumors with LOH, suggesting that this mutation resulted in loss of function of the receptor. Seven of 13 (54{\%}) LOH patients developed symptomatic radiation-induced lung injury vs. 1/12 (8{\%}) of patients without LOH (p = 0.05). Conclusions: Loss of the M6P/IGF2R gene strongly correlates with the development of radiation pneumonitis after thoracic radiotherapy (RT). Furthermore, patients with LOH (in the setting of measurable tumor) are much more likely to have elevated plasma TGFβ, suggesting an inability to normally process this cytokine. Thus, loss of the M6P/IGF2R gene may predispose patients to the development of radiation-induced lung injury.",
keywords = "Complications, Mannose 6-phosphate/insulin-like growth factor type 2 receptor, Radiation pneumonitis",
author = "Kong, {Feng Ming} and Anscher, {Mitchell S.} and Sporn, {Thomas A.} and Washington, {Mary K.} and Robert Clough and Barcellos-Hoff, {Mary H.} and Jirtle, {Randy L.}",
year = "2001",
month = "1",
day = "1",
doi = "10.1016/S0360-3016(00)01377-8",
language = "English (US)",
volume = "49",
pages = "35--41",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Loss of heterozygosity at the mannose 6-phosphate insulin-like growth factor 2 receptor (M6P/IGF2R) locus predisposes patients to radiation-induced lung injury

AU - Kong, Feng Ming

AU - Anscher, Mitchell S.

AU - Sporn, Thomas A.

AU - Washington, Mary K.

AU - Clough, Robert

AU - Barcellos-Hoff, Mary H.

AU - Jirtle, Randy L.

PY - 2001/1/1

Y1 - 2001/1/1

N2 - Purpose: To investigate the relationship between loss of heterozygosity (LOH) at the mannose 6-phosphate/insulin-like growth factor 2 receptor (M6P/IGF2R) gene locus and the development of radiation-induced lung injury. Material and Methods: Thirty-five lung cancer patients with both stored plasma for Transforming Growth Factor β1 (TGFβ1) analysis and sufficient quantities of archival pathology tissue to screen for LOH were studied. All patients had been treated with thoracic radiotherapy for their malignancy and had radiographically detectable tumor present before beginning radiotherapy. Tumor and normal cells were microdissected from archival lung cancer pathology specimens. Two polymorphisms in the 3′ untranslated region of the M6P/IGF2R were used to screen for LOH. Plasma TGFβ1 levels were measured using acid-ethanol extraction and an ELISA. TGFβ1 and M6P/IGF2R protein expression was estimated by immunofluorescence and immunohistochemical staining. Symptomatic radiation pneumonitis was scored according to National Cancer Institute Common Toxicity Criteria without knowledge of the results of TGFβ or LOH analyses. Results: Of the 35 patients, 10 were homozygous for this polymorphism (noninformative) and were excluded. Of the 25 informative patients, 13 had LOH. Twelve of 13 patients with LOH had increased pretreatment plasma TGFβ1 levels, vs. 3/12 patients without LOH (p < 0.01). A decrease or loss of M6P/IGF2R protein in the malignant cell accompanied by increased latent TGFβ1 protein in extracellular matrix and tumor stroma was found in tumors with LOH, suggesting that this mutation resulted in loss of function of the receptor. Seven of 13 (54%) LOH patients developed symptomatic radiation-induced lung injury vs. 1/12 (8%) of patients without LOH (p = 0.05). Conclusions: Loss of the M6P/IGF2R gene strongly correlates with the development of radiation pneumonitis after thoracic radiotherapy (RT). Furthermore, patients with LOH (in the setting of measurable tumor) are much more likely to have elevated plasma TGFβ, suggesting an inability to normally process this cytokine. Thus, loss of the M6P/IGF2R gene may predispose patients to the development of radiation-induced lung injury.

AB - Purpose: To investigate the relationship between loss of heterozygosity (LOH) at the mannose 6-phosphate/insulin-like growth factor 2 receptor (M6P/IGF2R) gene locus and the development of radiation-induced lung injury. Material and Methods: Thirty-five lung cancer patients with both stored plasma for Transforming Growth Factor β1 (TGFβ1) analysis and sufficient quantities of archival pathology tissue to screen for LOH were studied. All patients had been treated with thoracic radiotherapy for their malignancy and had radiographically detectable tumor present before beginning radiotherapy. Tumor and normal cells were microdissected from archival lung cancer pathology specimens. Two polymorphisms in the 3′ untranslated region of the M6P/IGF2R were used to screen for LOH. Plasma TGFβ1 levels were measured using acid-ethanol extraction and an ELISA. TGFβ1 and M6P/IGF2R protein expression was estimated by immunofluorescence and immunohistochemical staining. Symptomatic radiation pneumonitis was scored according to National Cancer Institute Common Toxicity Criteria without knowledge of the results of TGFβ or LOH analyses. Results: Of the 35 patients, 10 were homozygous for this polymorphism (noninformative) and were excluded. Of the 25 informative patients, 13 had LOH. Twelve of 13 patients with LOH had increased pretreatment plasma TGFβ1 levels, vs. 3/12 patients without LOH (p < 0.01). A decrease or loss of M6P/IGF2R protein in the malignant cell accompanied by increased latent TGFβ1 protein in extracellular matrix and tumor stroma was found in tumors with LOH, suggesting that this mutation resulted in loss of function of the receptor. Seven of 13 (54%) LOH patients developed symptomatic radiation-induced lung injury vs. 1/12 (8%) of patients without LOH (p = 0.05). Conclusions: Loss of the M6P/IGF2R gene strongly correlates with the development of radiation pneumonitis after thoracic radiotherapy (RT). Furthermore, patients with LOH (in the setting of measurable tumor) are much more likely to have elevated plasma TGFβ, suggesting an inability to normally process this cytokine. Thus, loss of the M6P/IGF2R gene may predispose patients to the development of radiation-induced lung injury.

KW - Complications

KW - Mannose 6-phosphate/insulin-like growth factor type 2 receptor

KW - Radiation pneumonitis

UR - http://www.scopus.com/inward/record.url?scp=0035174298&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035174298&partnerID=8YFLogxK

U2 - 10.1016/S0360-3016(00)01377-8

DO - 10.1016/S0360-3016(00)01377-8

M3 - Article

C2 - 11163495

AN - SCOPUS:0035174298

VL - 49

SP - 35

EP - 41

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 1

ER -